v3.26.3
Equity Method Investment
9 Months Ended
Sep. 30, 2026
Equity Method Investment [Abstract]  
EQUITY METHOD INVESTMENT

Note 4 — EQUITY METHOD INVESTMENT

AirJoule, LLC

On January 25, 2024, the Company entered into a Framework Agreement with GE Vernova Ventures LLC (formerly GE Ventures LLC), a Delaware limited liability company (“GE Vernova”), and, solely for the purposes specified therein, GE Vernova LLC, a Delaware limited liability company (“GE Vernova Parent”), pursuant to which the Company and GE Vernova agreed, subject to the terms and conditions of the Framework Agreement, including certain closing conditions specified therein, to form a joint venture in which each of the Company and GE Vernova will hold a 50% interest. The purpose of the AirJoule JV is to incorporate GE Vernova’s proprietary sorbent materials into systems that utilize the Company’s AirJoule water capture technology and to manufacture and bring products incorporating the combined technologies to market in the Americas, Africa and Australia. AirJoule, LLC is a variable interest entity for which the Company has determined there is shared power with GE Vernova; therefore the Company accounts for the VIE under the equity method of accounting.

The Company’s share of the income (loss) reported by AirJoule, LLC is recorded as an equity gain (loss) from investment in AirJoule, LLC in the accompanying condensed consolidated statements of operations.

The following table contains balance sheet information of AirJoule, LLC as of September 30, 2026 and December 31, 2025:

 

 

As of September 30,
2026

 

 

As of
December 31,
2025

 

Total current assets

 

$

962,186

 

 

$

660,788

 

In-process research and development

 

 

456,200,000

 

 

 

613,400,000

 

Goodwill

 

 

213,929,000

 

 

 

290,025,000

 

Other non-current assets

 

 

6,244,710

 

 

 

6,559,351

 

Total assets

 

$

677,335,896

 

 

$

910,645,139

 

Total current liabilities

 

$

2,935,063

 

 

$

3,338,471

 

Total non-current liabilities

 

 

4,149,080

 

 

 

4,512,028

 

Total liabilities

 

 

7,084,143

 

 

 

7,850,499

 

Members’ equity

 

$

1,252,803,100

 

 

$

1,236,803,100

 

Accumulated deficit

 

 

(582,551,347

)

 

 

(334,008,460

)

Total liabilities and members’ equity

 

$

677,335,896

 

 

$

910,645,139

 

 

AirJoule, LLC tests its intangible assets for impairment as of October 1 of each year, or whenever a change in events and circumstances (triggering event) occurs that indicates the fair value of intangible assets may be below their carrying values.

Given AirJoule, LLC’s status as an early-stage company with limited operating history and the uncertainties regarding AirJoule, LLC’s successful development and commercialization of its products, there can be no assurance that the estimates and assumptions made for purposes of its goodwill impairment testing in 2026 will prove to be accurate predictions of the future. If AirJoule, LLC’s assumptions, including timing of revenue generation and forecasted EBITDA, are not achieved, then AirJoule, LLC may be required to record goodwill impairment charges in future periods.

 

Based on triggering events, specifically a sustained decline in the Company’s stock price and other quantitative factors, AirJoule, LLC performed an interim impairment test as of September 30, 2026 on its in-process R&D and determined that the carrying value of its in-process R&D exceeded the respective fair value, resulting in an impairment of $46.9 million. The Company’s share of the in-process R&D impairment, $23.5 million, was recorded within equity loss from investment in AirJoule, LLC in the accompanying condensed consolidated statements of operations. Based on triggering events, specifically a sustained decline in the Company’s stock price, AirJoule, LLC performed an interim impairment test as of March 31, 2026 on its in-process R&D and determined that the carrying value of its in-process R&D exceeded the respective fair value, resulting in an impairment of $110.3 million. The Company’s share of the in-process R&D impairment reported by AirJoule, LLC was recorded as an equity loss from investment in AirJoule, LLC in the accompanying condensed consolidated statements of operations.

 

AirJoule, LLC also performed an interim impairment test on its goodwill as of September 30, 2026 and determined that the fair value exceeded the carrying value, concluding no impairment. As of March 31, 2026, AirJoule, LLC performed an interim impairment test on its goodwill and determined that the carrying value exceeded the respective fair value and recorded goodwill impairment charges of $76.1 million during the three months ended March 31, 2026. As a result, the Company reduced its basis difference by the Company’s share of AirJoule, LLC’s goodwill impairment charges. The Company’s basis difference was $105.8 million as of both March 31, 2026 and September 30, 2026.

 

The following table contains statement of operations information of AirJoule, LLC for the three and nine months ended September 30, 2026 and 2025:

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Revenue

$

23,993

 

 

 

—

 

 

$

23,993

 

 

 

—

 

Cost of sales

 

24,973

 

 

 

—

 

 

 

24,973

 

 

 

—

 

Gross loss

 

(980

)

 

 

—

 

 

 

(980

)

 

 

—

 

Operating expenses

 

(4,735,466

)

 

 

(4,045,745

)

 

 

(15,293,942

)

 

 

(12,995,206

)

In-process research and development impairment

 

(46,900,000

)

 

 

—

 

 

 

(157,200,000

)

 

 

—

 

Goodwill Impairment

 

—

 

 

 

(154,793,000

)

 

 

(76,096,000

)

 

 

(154,793,000

)

Other income

 

12,192

 

 

 

28,107

 

 

 

48,034

 

 

 

337,678

 

Net loss

$

(51,624,254

)

 

$

(158,810,638

)

 

$

(248,542,888

)

 

$

(167,450,528

)